Benjamin Hohl Sells 3,250 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Benjamin Hohl sold 3,250 shares of the firm’s stock in a transaction dated Thursday, February 27th. The stock was sold at an average price of $20.41, for a total transaction of $66,332.50. Following the sale, the chief financial officer now directly owns 13,000 shares in the company, valued at $265,330. This represents a 20.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Benjamin Hohl also recently made the following trade(s):

• On Wednesday, February 5th, Benjamin Hohl sold 1,000 shares of Enliven Therapeutics stock. The stock was sold at an average price of $22.52, for a total transaction of $22,520.00.
• On Monday, January 27th, Benjamin Hohl sold 3,250 shares of Enliven Therapeutics stock. The stock was sold at an average price of $21.59, for a total transaction of $70,167.50.
• On Friday, January 3rd, Benjamin Hohl sold 1,000 shares of Enliven Therapeutics stock. The stock was sold at an average price of $25.04, for a total transaction of $25,040.00.
• On Monday, December 30th, Benjamin Hohl sold 900 shares of Enliven Therapeutics stock. The stock was sold at an average price of $22.51, for a total transaction of $20,259.00.
• On Friday, December 27th, Benjamin Hohl sold 3,350 shares of Enliven Therapeutics stock. The stock was sold at an average price of $22.15, for a total transaction of $74,202.50.

Enliven Therapeutics Stock Performance

NASDAQ ELVN opened at $19.92 on Wednesday. Enliven Therapeutics, Inc. has a one year low of $10.90 and a one year high of $30.03. The company’s 50 day moving average price is $21.93 and its 200 day moving average price is $23.94. The firm has a market capitalization of $973.27 million, a price-to-earnings ratio of -10.48 and a beta of 1.03.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on ELVN shares. BTIG Research started coverage on shares of Enliven Therapeutics in a report on Friday, December 13th. They set a “buy” rating and a $42.00 price objective on the stock. Robert W. Baird raised their price target on shares of Enliven Therapeutics from $32.00 to $40.00 and gave the company an “outperform” rating in a report on Friday, November 15th. Four analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $38.25.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of ELVN. Quest Partners LLC raised its stake in shares of Enliven Therapeutics by 1,226.4% during the third quarter. Quest Partners LLC now owns 21,117 shares of the company’s stock valued at $539,000 after purchasing an additional 19,525 shares during the period. First Turn Management LLC raised its stake in shares of Enliven Therapeutics by 29.5% during the third quarter. First Turn Management LLC now owns 535,092 shares of the company’s stock valued at $13,666,000 after purchasing an additional 121,849 shares during the period. Charles Schwab Investment Management Inc. raised its stake in shares of Enliven Therapeutics by 10.4% during the third quarter. Charles Schwab Investment Management Inc. now owns 255,277 shares of the company’s stock valued at $6,520,000 after purchasing an additional 24,043 shares during the period. The Manufacturers Life Insurance Company raised its stake in shares of Enliven Therapeutics by 25.6% during the third quarter. The Manufacturers Life Insurance Company now owns 17,282 shares of the company’s stock valued at $441,000 after purchasing an additional 3,518 shares during the period. Finally, FMR LLC raised its stake in shares of Enliven Therapeutics by 10.6% during the third quarter. FMR LLC now owns 6,296,179 shares of the company’s stock valued at $160,804,000 after purchasing an additional 601,611 shares during the period. Hedge funds and other institutional investors own 95.08% of the company’s stock.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.